8,9,10,11-tetrahydro-3,8,11-triaza-benzo[a]fluoren-7-one | 837378-25-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 8,9,10,11-tetrahydro-3,8,11-triaza-benzo[a]fluoren-7-one
• 英文别名: 5,13,17-triazatetracyclo[8.7.0.02,7.011,16]heptadeca-1(10),2(7),3,5,8,11(16)-hexaen-12-one
• CAS: 837378-25-3
• 化学式: C₁₄H₁₁N₃O
• 分子量: 237.261
• InChiKey: QWQJKPPUDAAQOJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  57.8
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  8,9,10,11-tetrahydro-3,8,11-triaza-benzo[a]fluoren-7-one 在 盐酸 作用下， 以 甲醇 为溶剂， 生成 8,9,10,11-tetrahydro-3,8,11-triaza-benzo[a]fluoren-7-one hydrochloride
  参考文献：
  名称：

  WO2008/104475

  摘要：

  公开号：
• 作为产物：
  描述：

  4-(isoquinolin-5-ylamino)-5,6-dihydro-1H-pyridin-2-one 在 palladium diacetate 、 copper diacetate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 8,9,10,11-tetrahydro-3,8,11-triaza-benzo[a]fluoren-7-one
  参考文献：
  名称：

  WO2008/104475

  摘要：

  公开号：

文献信息

• Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
  申请人：Anderson R. David

  公开号：US20050137220A1

  公开（公告）日：2005-06-23

  A method is described for inhibiting mitogen activated protein kinase-activated protein kinase-2 in a subject in need of such inhibition, where the method involves administering to the subject a beta-carboline MK-2 inhibiting compound, or a pharmaceutically acceptable salt thereof.

  本文描述了一种用于抑制需要这种抑制的受试者中的有丝分裂原活化蛋白激酶激活蛋白激酶-2的方法，其中该方法涉及向受试者施用一种β-喀啉MK-2抑制化合物或其药学上可接受的盐。
• ISOQUINOLINOPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS
  申请人：Vanotti Ermes

  公开号：US20100056556A1

  公开（公告）日：2010-03-04

  Heteroarylpyridinone derivatives represented by formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , and X are as defined in the specification, compositions thereof, and methods of use thereof. Particularly, there are described isoquinolinoyrrolopyridinones, pharmaceutical compositions comprising them and their use as therapeutic agents in the treatment of cancer and cell proliferation disorders.

  公式（I）所代表的杂环芘啶酮衍生物，其中R1、R2、R3、R4、R5和X如规范所定义，以及它们的组合物和使用方法。特别地，描述了异喹啉基吲哚芘啶酮，包括它们的制药组合物以及它们在治疗癌症和细胞增殖障碍方面作为治疗剂的用途。
• Isoquinolinopyrrolopyridinones active as kinase inhibitors
  申请人：Nerviano Medical Sciences S.R.L.

  公开号：US08293762B2

  公开（公告）日：2012-10-23

  Heteroarylpyridinone derivatives represented by formula (I) wherein R1, R2, R3, R4, R5, and X are as defined in the specification, compositions thereof, and methods of use thereof. Particularly, there are described isoquinolinoyrrolopyridinones, pharmaceutical compositions including them and their use as therapeutic agents in the treatment of cancer and cell proliferation disorders.

  本发明涉及一种由式(I)表示的杂环芘啶酮衍生物，其中R1、R2、R3、R4、R5和X在说明书中定义，以及它们的组成物和使用方法。特别地，本发明描述了异喹啉基吲哚芘啶酮衍生物，包括它们的药物组合物以及它们作为治疗癌症和细胞增殖紊乱的治疗剂的使用。
• Methods and compositions for treating cellular proliferative diseases
  申请人：Yaffe B. Michael

  公开号：US20060115453A1

  公开（公告）日：2006-06-01

  The present invention relates to compounds and pharmaceutical compositions for treating cellular proliferative disorders, screening assays for identifying such compounds, and methods for treating such disorders.
• Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells
  申请人：Yaffe Michael B.

  公开号：US20090010927A1

  公开（公告）日：2009-01-08

  The present invention relates to compounds and pharmaceutical compositions for treating cellular proliferative disorders, e.g., in patients having one or more p53-deficient cells, screening assays for identifying such compounds, and methods for treating such disorders.